Yahoo Finance

AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa to Treat Primary Monogenic IL-18 Driven HLH

Potential new treatment option in ultra-rare, life-threatening, primarily pediatric disease with no approved therapies Lausanne (Switzerland), March 7, 2023 -- AB2 Bio Ltd., a biotechnology company ...
Yahoo Finance

AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease

Agreement grants Nippon Shinyaku an option to acquire exclusive U.S. rights to commercialize AB2 Bio’s Tadekinig alfa to treat Primary Monogenic IL-18 driven Hyperinflammatory Syndrome in patients ...
Nasdaq

WuXi Biologics and AB2 Bio Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa

Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH) WuXi Biologics to undertake ...
BioWorld

Already a life saver: AB2 Bio advancing its IL-18-binding protein

DUBLIN – Swiss orphan drug developer AB2 Bio Ltd. has obtained dramatic clinical proof of concept for its recombinant interleukin-18-binding protein (IL-18BP) therapy (tadekinig alfa), in an ...
Hosted on MSN

AB2 Bio and Nippon Shinyaku enter Tadekinig alfa licensing deal

AB2 Bio has made an option and licencing agreement with Nippon Shinyaku, granting the latter the option to obtain exclusive rights to commercialise Tadekinig alfa in the US. This therapy treats a rare ...
BioWorld

AB2 Bio, Nippon Shinyaku in $686M deal for IL-18 drug tadekinig

Inflammatory diseases specialist AB2 Bio Ltd. has signed a potential $686 million U.S. commercialization deal for its interleukin-18 neutralizing drug tadekinig. The agreement with Japanese pharma ...